What is Accendra Health's gross profit margin?

What is Accendra Health's latest dividend and current dividend yield?

What were the key takeaways from Accendra Health's earnings call?

What were the key takeaways from Accendra Health’s earnings call?

What guidance did Accendra Health's management provide for the next earnings period?

What factors drove the changes in Accendra Health's revenue and profit?

What is the market's earnings forecast for Accendra Health next quarter?

Did Accendra Health beat or miss consensus estimates last quarter?

- **Strategic Restructuring**: Sold P&HS segment to Platinum Equity, repositioning as pure-play home-based care company with $2.1B net debt.
- **Patient Direct Growth**: 3.4% YTD revenue growth in Q3 2025, driven by sleep therapy and diabetes adherence programs.
- **Optum Partnership**: New preferred provider agreement targets 100,000+ healthcare providers, positioning to offset 2026 Kaiser contract loss.
- **Financial Health**: 2025 free cash flow of $78M (YTD), with 2026 outlook improving post-divestiture and stranded cost reduction.
- **Market Opportunity**: 96M prediabetic patients and 85M undiagnosed sleep apnea patients represent secular growth tailwinds.

**【CEO Opening Remarks】**
- Announced definitive agreement to sell Products & Healthcare Services (P&HS) segment to Platinum Equity, retaining equity stake. Rebranding as a pure-play home-based care company post-divestiture in Q1 2026.
- Patient Direct segment will focus on high-margin chronic care (diabetes, sleep apnea), with 37M diabetes patients and 85M undiagnosed sleep apnea patients in the U.S.
- Strategic investments in AI, automation, and cost reduction to improve patient experience and scale operations.
- Signed preferred provider agreement with Optum, leveraging 450 sales reps to target 100,000+ referral sources.

**【CFO Financial Commentary】**
- Q3 2025 revenue: $697M (3.4% YTD growth), driven by sleep therapy, ostomy, and urology. Adjusted EBITDA: $92M (down 15% YoY due to one-time $6M benefit in 2024).
- Full-year 2025 guidance: Revenue $2.76-2.82B, adjusted EBITDA $376-382M, adjusted EPS $1.02-1.07.
- Net debt: $2.1B (includes $100M Rotech exit costs and P&HS kitting facility overstock). Free cash flow from continuing ops: $28M (Q3) / $78M (YTD).

**【Q&A Highlights】**
- **2026 Outlook**: CEO expects strong organic growth in home-based care, offsetting loss of unprofitable Kaiser contract. CFO notes 2026 free cash flow will improve with stranded costs reduction.
- **Optum Agreement**: Early-stage, with potential to replace lost Kaiser margins with fewer new contracts.
- **P&HS Cash Flow Issues**: $100M+ inventory overstock for new kitting facility, expected to normalize in Q1 2026.
- **Balance Sheet Risk**: No covenant breaches; comfortably compliant with lenders.
- **Preferred Provider Agreements**: Focus on high-margin chronic care, with 96M prediabetic patients as growth opportunity.

Owens & Minor, Inc. (OMI) Q3 2025 Earnings Call Transcript

- **Strategic Restructuring Complete**: P&HS divestiture finalized, with 100% of sale proceeds allocated to debt reduction.
- **Patient Direct Growth Accelerates**: 2025 revenue guidance of $2.76-$2.82 billion (+4.5% YoY), driven by sleep supplies and urology/ostomy categories.
- **Cost Management Success**: Adjusted EBITDA margin expands to 14.2%, with stranded costs down 35% YoY to $11 million in Q2.
- **Key Risk Mitigation**: Diabetes revenue shift to pharmacy mitigates top-line impact, while competitive bidding risks remain limited to <20% of revenue.
- **Leverage Reduction Path**: Target 2x-3x EBITDA leverage, with net debt expected to decline post-P&HS sale.

**【CEO Summary Section】**
- Owens & Minor has divested its Products & Healthcare Services (P&HS) segment, now classified as discontinued operations, to focus exclusively on its higher-margin Patient Direct business.
- Patient Direct revenue is projected to grow to $2.76-$2.82 billion in 2025, with adjusted EBITDA of $376-$382 million, driven by sleep, urology, and ostomy categories.
- The company terminated its Rotech acquisition due to regulatory challenges, redirecting $80 million in costs to debt reduction.
- Strategic priorities include mitigating stranded costs, reducing debt, advancing IT automation, and pursuing smaller, additive acquisitions.

**【CFO Financial Commentary】**
- Q2 2025 revenue: $682 million (+3.3% YoY), with sleep supplies leading growth at 4.5% YoY.
- Adjusted EBITDA: $96.6 million (14.2% margin), up from $91.1 million (13.8% margin) in Q2 2024, driven by volume growth and cost savings.
- Stranded costs: $11 million in Q2 2025 (vs. $17 million in Q2 2024), expected to rise temporarily before declining post-divestiture.
- Net debt: $1.9 billion as of June 30, 2025, with 100% of P&HS sale proceeds allocated to debt reduction.
- 2025 guidance: Revenue $2.76-$2.82 billion, adjusted EBITDA $376-$382 million, adjusted EPS $1.02-$1.07.

**【Q&A Key Highlights】**
- **Stranded Costs Timeline**: CFO Jon Leon expects Q2 2025 stranded costs ($11 million) to represent the near-term run rate, with reductions beginning in 2026 post-divestiture.
- **Diabetes Business Shift**: 40% of diabetes revenue has shifted from DME to pharmacy, reducing top-line growth but maintaining profitability through internal pharmacy channels.
- **Competitive Bidding Impact**: <20% of revenue exposed to Medicare competitive bidding, with potential 2028-2029 pricing impacts offset by scale advantages.
- **Kaiser Contract Transition**: 2025 impact minimal, with 2026 focusing on capturing new business opportunities post-capitated contract transition.
- **Free Cash Flow**: Projected at $60-$70 million annually, excluding P&HS-related interest expenses.
- **Acquisition Strategy**: Future deals will be smaller, additive bolt-ons focused on Patient Direct capabilities.

Owens & Minor, Inc. (OMI) Q2 2025 Earnings Call Transcript

- **Patient Direct Growth**: 6% YoY revenue rise, 31% op income increase, and 173bp margin expansion highlight segment strength. Sleep supplies and new distribution centers drive momentum.
- **Tariff Mitigation**: $100M-$150M annual P&HS tariff exposure to be passed via direct price hikes, preserving critical supply access amid 1% margin constraints.
- **Financial Performance**: Q1 adjusted EPS up 20% to $0.23, EBITDA +5%. Cost control cuts DS&A by 1.4%, offsetting P&HS margin pressure.
- **Rotech Update**: Acquisition financing finalized, with accretion expected in 2026. Deal closure pending FTC approval in early June.
- **Cash Flow Outlook**: Sequential improvement after Q1 working capital build, targeting 2x-3x EBITDA leverage by year-end.

**【CEO Summary Section】**
- **Patient Direct Segment**: Q1 revenue grew 6% YoY (7.3% same-day basis), driven by sleep supplies (+high single digits), wound/ostomy/urology (+double digits), and home respiratory expansion. Operating income rose 31% ($14M), with a 173bp margin expansion. Sleep Journey initiative boosted starts and resupply adherence. New distribution centers in WV and SD opened, supported by WVU and Upper Midwest contracts.
- **P&HS Segment**: Q1 revenue $1.96B, down 0.8% as reported (0.7% same-day growth). Medical Distribution saw same-store sales growth but offset by lower glove prices and intl sales. Proprietary product penetration increased. Rotech acquisition awaits FTC approval, with $100M-$150M annual tariff exposure. Price increases for P&HS products to begin in early June, targeting tariff-affected SKUs.
- **Tariff Impact**: 2025 exposure estimated at $100M-$150M, primarily in P&HS. Company mitigating via inventory build, U.S. manufacturing, and alternative sourcing. Price hikes will pass costs to customers, with focus on preserving critical supply access.

**【CFO Financial Commentary】**
- **Q1 2025 Results**: Total revenue $2.6B (+1% as reported, +2.3% same-day). Adjusted net income $18M ($0.23 EPS), up 20% YoY. Adjusted EBITDA $122M (+5%). Patient Direct gross margin +40bps, offset by P&HS margin decline due to nitrile costs and FX. DS&A expenses down 1.4% YoY to $462M (17.6% of revenue), driven by cost control and facility buildouts.
- **Cash Flow**: Q1 cash outflow due to P&HS inventory build, tariff mitigation, and $23M in acquisition/sale-related costs. Expecting sequential improvement in cash flow, with H2 2025 generating ~70% of annual earnings and cash flow. Debt reduction target: 2x-3x EBITDA leverage ratio.

**【Q&A Highlights】**
- **Tariff Strategy**: Direct SKU-level price increases for tariff-affected products, avoiding blended approaches. Working with customers to substitute lower-cost alternatives. 2025 exposure concentrated in P&HS, with minimal impact on Patient Direct.
- **FX Impact**: Q1 P&HS margin hurt by Asian currency volatility. Expecting stability in 2025 H2, with guidance unchanged.
- **Rotech Acquisition**: Debt financing in place, with interest ~50bps higher than initial estimate. Neutral accretion in first full year, +$0.15 EPS in second year. Deal closure expected in early June.
- **Free Cash Flow**: Despite Q1 working capital strain, reaffirmed guidance for meaningful 2025 FCF ($100M+), driven by H2 growth and margin recovery.

Owens & Minor (OMI)-8 May 25-2025 Q1 Earnings call transcript

- **Debt Reduction & Flexibility**: $647M debt paid over 2 years, enabling $100M share buyback and Rotech integration. 
- **Patient Direct Momentum**: Mid-single-digit growth, $13M+ op income expansion, diabetes supplies outperforming. 
- **2025 Outlook**: $200M+ free cash flow for debt, $575M EBITDA midpoint, and $1.73 EPS guidance. 
- **Rotech Synergies**: $50M+ cost savings achievable within 3 years, with potential acceleration. 
- **Risks**: Tariffs (1.5% P&HS exposure), capitated contract pricing, and Q1 seasonality.

**【CEO Summary Section】**
- **Strategic Progress**: Completed $647M debt repayment over 2 years, enhancing financial flexibility for Rotech acquisition. 
- **Patient Direct Growth**: Mid-single-digit revenue growth in 2024, $13M+ incremental operating income, driven by diabetes supplies and smaller category expansion. 
- **Rotech Synergies**: Target $50M+ cost synergies by Year 3, with potential acceleration post-regulatory approval. 
- **2025 Focus**: Free cash flow for debt reduction ($200M+), disciplined reinvestment, and Rotech integration. 

**【CFO Financial Commentary】**
- **2024 Results**: Revenue $10.8B (1.5% Q4 growth), Adjusted EPS $0.55, EBITDA $575M midpoint for 2025. 
- **2025 Guidance**: Revenue $10.85B-$11.15B, EBITDA $560M-$590M, EPS $1.60-$1.75. 
- **Cash Flow**: $200M+ for debt reduction, $100M share buyback authorized. 
- **Risks**: Tariffs (1.5% of P&HS revenue), capitated contract pricing changes, and Q1 seasonality. 

**【Q&A Key Takeaways】**
- **Rotech Update**: No surprises in 2024 results; $50M+ synergies achievable within 3 years. 
- **Free Cash Flow Deployment**: Debt reduction first priority, with opportunistic buybacks if stock undervalued. 
- **Tariff Impact**: Minimal (1.5% of P&HS revenue from Mexico), manageable via customer price pass-through. 
- **NIV/Oxygen Recovery**: Encouraging Q4 trends, targeting growth acceleration in 2025. 
- **P&HS Sale Process**: Strong interest, aiming for decision in 2025. 
- **Apria Contract**: Minimal 2025 impact; disciplined approach to capitated contracts.

ACH

ACH fundamentals

Earnings Call

You can ask Aime